about
Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsyUpdate on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatristsBenign familial neonatal convulsions (BFNC) resulting from mutation of the KCNQ2 voltage sensorAnticonvulsant properties of an oral ketone ester in a pentylenetetrazole-model of seizureClinical Guidelines for Management of Bone Health in Rett Syndrome Based on Expert Consensus and Available EvidenceMozart's music in children with drug-refractory epileptic encephalopathies.Anticonvulsant drugs and hematological disease.Malignant migrating partial seizures in infancy: an epilepsy syndrome of unknown etiology.A low cost amplifier and acquisition system for cortical-electroncephalography in non-human applicationsNutritional problems in children with neuromotor disabilities: an Italian case seriesThe ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience.Cerebellar vermis defect, oligophrenia, congenital ataxia, and hepatic fibrocirrhosis without coloboma and renal abnormalities: report of three cases.Bone and calcium metabolism and antiepileptic drugs.Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform.Treatment of partial seizures in childhood : an overview.Teachers of various school grades and representations of epilepsy: problems, relational aspects and perspectives of life qualityEpilepsy and electroencephalographic anomalies in chromosome 2 aberrations. A review.Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review.Epilepsy, sex hormones and antiepileptic drugs in female patients.New developments in the management of partial-onset epilepsy: role of brivaracetam.Catamenial epilepsy: hormonal aspects.Hormonal and reproductive disturbances in epileptic male patients: emerging issues.The ketogenic diet for Dravet syndrome and other epileptic encephalopathies: an Italian consensus.Should "migralepsy" be considered an obsolete concept? A multicenter retrospective clinical/EEG study and review of the literature.Update on rufinamide in childhood epilepsy.Non-resective surgery and radiosurgery for treatment of drug-resistant epilepsy.Malignant migrating partial seizures in infancy.Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.Epilepsy in children with Menkes disease: a systematic review of literature.Neuropsychological impairment in childhood absence epilepsy: Review of the literature.Current role of perampanel in pediatric epilepsy.Anticonvulsant drugs for generalized tonic-clonic epilepsy.The clinical phenotype of autosomal dominant lateral temporal lobe epilepsy related to reelin mutations.Ketogenic diet and childhood neurological disorders other than epilepsy: an overview.Ketogenic diet for the treatment of catastrophic epileptic encephalopathies in childhood.Heterozygous reelin mutations cause autosomal-dominant lateral temporal epilepsy.Refractory absence seizures: An Italian multicenter retrospective study.Conduct disorders and psychopathy in children and adolescents: aetiology, clinical presentation and treatment strategies of callous-unemotional traitsLong-term outcome of autistic spectrum disorder: a retrospective case study in a southern italian region.Temporal lobe dual pathology in malignant migrating partial seizures in infancy.
P50
Q26745780-F141E793-0E97-4847-A0FA-014B4BBD6857Q26747123-955AFF65-47DB-4149-82F6-FE613F02C051Q28200021-42B9172F-7F1B-428D-B858-1953A0F8CC8AQ28262623-6EBA2EA1-4603-4567-94D1-BBC0DE9BAEC6Q28553154-FE305FAA-96F4-47C9-BCFE-7E2FB4AAEF64Q30375914-2AAD2FAA-3A89-42F8-957F-C3597813A8C6Q33413868-EFEF0B68-521E-413E-B0B4-795BD55EE49DQ33452789-DF305376-3D6F-4314-927B-8C2A63CBDB6EQ33575399-C73EB073-57B9-4868-A781-89E6CAD41EAAQ34034592-E3F7143A-8D85-4D73-AF36-A898ECA476CDQ34119523-F2F343C6-7C14-4C68-923F-F1974D641057Q34153357-8EA0ACFE-1931-49CA-AFAC-987593634587Q34613804-15F1065C-FD9F-4DA8-85DB-98278DA0B454Q35079979-401F87E1-5BC8-4A2D-868B-502DE845C475Q35660930-9D5D6DC4-BAC5-4643-9DDF-7447544F5C11Q35799741-6AA64213-A7F5-415F-A57D-13B50133A50CQ37086728-87BA186E-9A1C-439C-A9A1-FBFC98A6F078Q37219705-39F3AE2E-43FE-48CC-90A1-E8F607018259Q37642006-926C2D06-A7B4-41DD-90F7-6044AFDD82FAQ37693757-B5889C3A-E95B-45B5-A33F-97400E346A11Q37762266-3D7C9ADD-8026-4159-B7F5-8A5C5AB5A9FDQ37845482-133D6D4E-8F1E-41F0-AFDA-CAF415E73F73Q37861273-F7BA01C8-1EFF-4CC8-A069-20A821FDD5BCQ37865830-3CC66203-4A0E-4132-8D78-25CA758E3EA1Q37906275-0D807E62-C558-45EE-BE97-0E245C124065Q37975838-4B6177D4-3256-40EA-8E8D-62A6EC9C1C0BQ38102165-ACAD5AD4-452C-4C04-8628-2A71387E4E08Q38220275-635D98AD-928C-4213-B495-3B3044D0E04EQ38231158-BC0117FA-3EE8-4AFD-8444-A6AA6B6E1DD5Q38670308-7845BF20-6DA8-414B-B34F-EF9FA6300304Q38675314-454CA59A-1721-495B-9D78-D7BB939BB1D2Q38798288-BCCAFC52-6A4F-437E-9FE2-93E3C5190910Q38988682-A0345028-ADF7-42CA-903F-EC1C2AFF01CDQ39007510-BD9BF4A1-07E5-4B9D-9E97-A7FB90C0E717Q40383938-992A8560-B084-4F4A-8224-0BDBFE7A6767Q40866479-3AD77739-C415-44ED-9402-5413C76B7111Q41518007-AD630072-CA38-4267-B9FD-93BC7A5EF417Q41696244-F35B2A67-9271-4691-803D-E9B1CF17B982Q41696256-EE25F31F-D695-4232-BE4A-553F0B9F3C55Q41918466-347BDE34-371C-4601-A927-AE575D6A2CF7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giangennaro Coppola
@ast
Giangennaro Coppola
@en
Giangennaro Coppola
@es
Giangennaro Coppola
@sl
type
label
Giangennaro Coppola
@ast
Giangennaro Coppola
@en
Giangennaro Coppola
@es
Giangennaro Coppola
@sl
prefLabel
Giangennaro Coppola
@ast
Giangennaro Coppola
@en
Giangennaro Coppola
@es
Giangennaro Coppola
@sl
P106
P21
P31
P496
0000-0002-9574-0081